Research programme: TREM-1 targeted therapeutics - Novo Nordisk

Drug Profile

Research programme: TREM-1 targeted therapeutics - Novo Nordisk

Alternative Names: hTREM1-IgG fusion protein - Novo Nordisk; TREM-1 - Novo Nordisk

Latest Information Update: 05 Sep 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioXell SpA
  • Developer Novo Nordisk
  • Class Proteins
  • Mechanism of Action TREM modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Inflammatory bowel diseases; Septic shock

Most Recent Events

  • 12 Mar 2010 BioXell SpA has been acquired and merged into Cosmo Pharmaceuticals
  • 30 Dec 2009 Novo Nordisk acquires the TREM-1 research programme from BioXell
  • 30 Dec 2009 Preclinical trials in Inflammation in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top